Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase ll study consisting S-1 + CDDP (SP) and Capecitabin + CDDP (XP) for adversed/metastatic gastric cancer with mesurable lesions and HER2 negative tumor (HERBIS-4A).

Trial Profile

A randomized phase ll study consisting S-1 + CDDP (SP) and Capecitabin + CDDP (XP) for adversed/metastatic gastric cancer with mesurable lesions and HER2 negative tumor (HERBIS-4A).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms HERBIS-4A
  • Most Recent Events

    • 02 Jul 2022 Results integrated analysis of three phase II randomized trials (HERBIS-2, HERBIS-4A, and XParTS II) with the use of individual participant data (IPD) from each trial, presented at the 24th World Congress on Gastrointestinal Cancer.
    • 25 Jan 2020 Results of pooled analysis from HERBIS-2 and HERBIS-4A studies presented at the 2020 Gastrointestinal Cancers Symposium.
    • 20 Feb 2019 Status changed to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top